A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo
Open Access
- 1 December 2009
- journal article
- Published by Elsevier in The American Journal of Surgery
- Vol. 198 (6) , 781-786
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Platinum neurotoxicity pharmacogeneticsMolecular Cancer Therapeutics, 2009
- Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patientsBreast Cancer Research and Treatment, 2008
- Platinum-based chemotherapy in triple-negative breast cancerAnnals of Oncology, 2008
- Intralymphatic Chemotherapy Using a Hyaluronan–Cisplatin ConjugateJournal of Surgical Research, 2008
- Long-term Results of Hyperthermic, Isolated Limb Perfusion for MelanomaAnnals of Surgery, 2007
- A New Model for Lymphatic Metastasis: Development of a Variant of the MDA-MB-468 Human Breast Cancer Cell Line that Aggressively Metastasizes to Lymph NodesClinical & Experimental Metastasis, 2005
- Is breast cancer survival improving?Cancer, 2003
- Comparative Adverse Effect Profiles of Platinum DrugsDrug Safety, 1995
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995
- Antitumor activity of a new series of platinum complexesAnti-Cancer Drugs, 1993